REGULATORY
3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
By Ken Yoshino November 21, 2024
The ruling coalition of the Liberal Democratic Party (LDP) and Komeito clinched an agreement with the opposition Democratic Party for the People (DPP) on a draft revision of a new economic package on November 20.…

LATEST

November 21, 2024
A throng of new medicines hit the Japanese market on November 20 upon their reimbursement listing, including Amgen’s Tepezza (teprotumumab) and Gilead Sciences’ Trodelvy (sacituzumab govitecan). Eli Lilly’s Alzheimer’s therapy Kisunla (donanemab) is set for…
November 21, 2024
Janssen Pharmaceutical (J&J) on November 20 filed a new drug application for its investigational multiple myeloma treatment talquetamab in Japan, the company said.Talquetamab is a T-cell redirecting bispecific antibody that binds to the CD3 receptor on the surfaces of T…
November 21, 2024
Only a week after its launch, Terumo’s generic versions of the long-acting local anesthetic agent Anapeine (ropivacaine) are already under restricted shipments.The major medical devices manufacturer launched two generic versions of Anapeine on November 12,…
By Ken Yoshino

Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…

By Philip Carrigan

For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA